STE Q1 2026: Free cash flow up $50M as backlog offsets tariff surge
- Robust order growth and strong backlog: The discussion highlighted sustained order intake and a solid backlog in both Healthcare and Life Sciences segments, suggesting a durable pipeline that can drive future revenue growth.
- Healthy cash generation and financial flexibility: The call underscored impressive free cash flow performance and a trend of building cash reserves—providing resources for strategic M&A, share buybacks, or other value-enhancing opportunities.
- Resilient operational positioning: The company’s proactive hedging against FX impacts, streamlined compliance investments in newer EO facilities, and capital business positioning in evolving ASC markets help protect margins and support continued expansion.
- Increased Tariff Exposure: Management reported tariffs on steel and aluminum rising from 25% to 50%, along with significant increases for copper (0% to 50%) and the EU (10% to 15%). These escalations could compress margins if cost pass-through proves challenging.
- Rising Employee Health Care Costs: The Q&A highlighted that increased utilization of employee health care benefits and corresponding premium hikes, even if in low single digits, are adding pressure on operating expenses, potentially impacting profitability.
- Hospital Reimbursement Uncertainty: Concerns were raised regarding potential challenges from OB3 and declining Medicaid exchange coverage. Although management framed it as mainly a payment issue, uncertainty in reimbursement could eventually dampen hospital demand and impact order volumes.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
As-reported revenue growth | FY 2026 | 6% to 7% | 8% to 9% | raised |
Constant currency organic revenue growth | FY 2026 | 6% to 7% | 6% to 7% | no change |
Segment revenue growth | FY 2026 | 6% to 7% | 6% to 7% | no change |
Adjusted EPS | FY 2026 | $9.90 to $10.15 | $9.90 to $10.15 | no change |
EBIT margins | FY 2026 | Expected to increase by 20 basis points | Expected to be about flat at the high end | lowered |
Effective tax rate | FY 2026 | Approximately 23.5% | Approximately 23.5% | no change |
Free cash flow | FY 2026 | Expected to be lower than fiscal 2025 | Increased by $50 million to $820 million | raised |
Capital expenditures | FY 2026 | no prior guidance | Unchanged at $375 million | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Consistent robust order growth and strong backlog | In Q4 2025, Healthcare orders grew by about 12% with a comfortable backlog and Life Sciences showed a rebound in orders; Q3 2025 emphasized strong Healthcare order growth (10% with a higher-than-expected backlog) and cautious optimism in Life Sciences; Q2 2025 highlighted robust Healthcare order growth (up to 30%) and strong consumable demand supporting Life Sciences | Q1 2026 reported Healthcare capital equipment revenue up 6% with 14% underlying order growth and a backlog just over $400 million; in Life Sciences, backlog increased over 50% to $111 million, reflecting recovery from previous slowdowns | Sustained strength in order growth with enhanced Life Sciences recovery compared to earlier uncertainty |
Robust financial management and healthy cash generation | Q4 2025 showed record free cash flow, disciplined debt reduction and readiness for M&A; Q3 2025 demonstrated strong free cash flow and effective debt management; Q2 2025 emphasized free cash flow progress with share repurchases and controlled capital expenditures | Q1 2026 generated $327 million in free cash flow, reduced total debt to $1.9 billion, and highlighted ongoing dividend growth, share buybacks, and strategic flexibility for M&A | Consistent financial strength continues with robust cash flow generation and strategic capital allocation |
Persistent tariff exposure challenges and evolving mitigation strategies | Q4 2025 noted a net tariff cost of $30 million with active supply chain adjustments; Q3 2025 described a wait‐and‐see approach with ongoing analysis; Q2 2025 did not explicitly address tariffs | Q1 2026 reported increased tariffs on metals (with steel, aluminum, and copper tariffs rising) and updated the earnings outlook to reflect $45 million in tariff costs, while favorable FX effects helped offset the increases | Tariff pressures have escalated, but clearer, proactive mitigation strategies and FX offsets are now in place |
Emerging focus on applied sterilization technologies (AST) with shifting growth sentiment | Q4 2025 detailed AST revenue growth of around 9% with variability in capital equipment shipments and a cautious FY outlook; Q3 2025 reported 10% growth with cautious optimism amid bioprocessing challenges; Q2 2025 saw a revision to high single‐digit growth as bioprocessing recovery lagged | Q1 2026 reported 10% constant currency organic revenue growth in AST, with improved EBIT margins rising to 48.6% and maintained a 6%–7% organic revenue growth expectation for FY 2026, while also noting proactive regulatory compliance | Growth in AST remains consistent with improved margins and a stable outlook, even though caution persists on long‐term growth guidance |
Healthcare capital equipment supply chain and delivery challenges | Q4 2025 did not highlight major issues; Q3 2025 noted delays due to customer readiness and project timing; Q2 2025 mentioned weather‐related delays affecting shipments | Q1 2026 did not mention any specific supply chain or delivery challenges, with strong order growth and a solid backlog reported | Earlier issues, such as delays from customer readiness and weather, have subsided in Q1 2026, suggesting resolution of prior supply chain concerns |
Rising operating cost pressures (labor, energy, and employee healthcare costs) | Q4 2025 discussed labor and energy cost pressures that were mostly offset through pricing and productivity improvements; Q3 2025 highlighted increased labor costs, higher energy prices, and significant additional employee healthcare expenses; Q2 2025 again identified labor and energy as key cost challenges | Q1 2026 acknowledged rising labor, energy, and employee healthcare costs, yet benefits from additional volume and pricing helped boost margins (e.g. in AST margins up by 150 basis points) | Cost pressures continue to be a challenge but are being effectively managed through improved pricing and increased operational volume |
Life Sciences segment uncertainty amid destocking and declining equipment revenue | Q4 2025 revealed significant declines in capital equipment revenue with a late-year rebound creating a strong backlog; Q3 2025 noted declines in equipment revenue combined with destocking issues, yet consumables growth provided optimism; Q2 2025 showed modest equipment revenue declines offset by robust consumable demand and a flat overall outlook | Q1 2026 highlighted a clear recovery in Life Sciences with strong order intake and a backlog increase of over 50% to $111 million, indicating a turnaround from prior equipment revenue declines | Sentiment has shifted from uncertainty due to destocking to positive recovery, as evidenced by significantly improved backlogs and order recovery |
Enhanced operational risk management through FX hedging and compliance investments | Q4, Q3, and Q2 2025 did not discuss this topic [N/A] | Q1 2026 detailed that the company is naturally hedged in FX—with FX benefits offsetting tariff costs—and emphasized proactive compliance investments (e.g., engineering modifications under NESHAP) | A new focus emerging in Q1 2026, highlighting proactive risk management and compliance which could strengthen future operational resilience |
Reshoring and front-shoring trends in the Asia-Pacific region as a new growth driver | Q2 2025 mentioned significant reshoring and front-shoring trends, especially in Malaysia, indicating strong regional growth; Q4 2025 referenced onshoring in a theoretical context, while Q3 2025 did not mention this topic | Q1 2026 did not mention reshoring or front-shoring trends in the Asia-Pacific region [N/A] | The topic appears to have faded from recent discussion, indicating it is no longer a primary growth driver in the current period |
Hospital reimbursement uncertainty and legal settlement cash flow impacts | In Q3 2025, hospital reimbursement uncertainty was noted as having minimal impact; Q4 2025 discussed a planned $40 million legal settlement payment impacting cash flow; Q2 2025 did not have any discussion of these topics | Q1 2026 addressed hospital reimbursement uncertainty as a payment challenge for customers, though it did not affect procedure volumes; legal settlement cash flow impacts were not mentioned in this period | Hospital reimbursement uncertainty has emerged again as a concern, while legal settlement cash flow issues seem to have faded from current discussions |
-
Cash Allocation
Q: How will cash be deployed?
A: Management indicated that with a strong cash balance and minimal prepayable debt, they plan to continue building cash while remaining active on M&A and buybacks to offset dilution, reflecting a deliberate and opportunistic capital allocation approach. -
Free Cash Flow
Q: Why is free cash flow up?
A: They highlighted that improved working capital—specifically in inventory and receivables—is lifting free cash flow by about $50M, even as earnings guidance remains unchanged. -
Tariff Impact
Q: What drove the tariff increase?
A: The CFO explained that tariffs on metals, including an increase from 25% to 50% on steel and aluminum and similar upticks on copper and EU imports, have raised overall tariff exposure. -
Revenue & Order Growth
Q: How strong is order growth?
A: The CEO stressed robust order growth across healthcare and life sciences segments, with substantial backlog levels confirming confidence in full-year revenue guidance. -
FX Hedging
Q: Are FX risks hedged?
A: Management confirmed that FX exposures are largely hedged, with a beneficial impact of approximately 200 basis points on revenue that neutralizes the overall FX effect. -
AST Outlook
Q: Is AST growth sustainable?
A: Despite a strong first quarter, management maintained a conservative outlook of 6–7% constant currency organic growth for AST, reflecting cautious optimism amid market uncertainties. -
Life Sciences & Bioprocessing
Q: How is the life sciences business trending?
A: The CEO noted that after past cyclical slowdowns, the life sciences backlog and bioprocessing volumes have steadied, pointing to strong order intake that bodes well for future demand. -
ASC Capital Business
Q: What’s the view on ASC opportunities?
A: He mentioned that the shift of procedures to ASCs presents a capital opportunity; their new equipment and training programs are well tailored to capture demand in these settings. -
EO Regulatory Relief
Q: Why skip EO regulatory relief?
A: Management emphasized that their newer EO facilities already comply with standards, so they did not pursue regulatory relief, avoiding unnecessary modification costs. -
Competitor Sterilization
Q: Impact from competitor sterilization issues?
A: The CEO observed that despite concerns raised by competitors over low-temperature sterilization, they have not experienced any slowdown in volumes, reinforcing confidence in their market position. -
Employee Healthcare Costs
Q: Why are healthcare benefits rising?
A: The CFO noted modest, low single-digit premium increases driven by higher utilization of employee benefits, a trend seen across the managed care market.
Research analysts covering STERIS.